NTRA - Natera - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Prenatal, Genetic, Cancer, NIPT, Transplantation

Natera Inc. is a pioneering diagnostics company that develops and commercializes innovative molecular testing services globally. Its extensive product portfolio includes Panorama, a groundbreaking non-invasive prenatal test that screens for chromosomal abnormalities in fetuses, including twin pregnancies.

The company's Horizon carrier screening test empowers individuals and couples to determine if they are carriers of genetic variations that cause certain genetic conditions. Additionally, Vistara, a single-gene NIPT, screens for 25 severe single-gene disorders that cause skeletal, cardiac, and neurological conditions.

Spectrum, a preimplantation genetic test, supports couples undergoing IVF, while Anora analyzes miscarriage tissue from women. Empower, a hereditary cancer screening test, provides valuable insights for patients. The company also offers a non-invasive prenatal paternity product, allowing couples to establish paternity before the child is born.

In the oncology space, Natera's Signatera is a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer. Altera, a tissue-based comprehensive genomic profiling test, provides further insights. Prospera assesses active rejection in patients who have undergone kidney, heart, and lung transplantation, while Renasight is a kidney gene panel test.

The company's Constellation is a cloud-based software product that enables laboratory customers to access Natera's algorithms and bioinformatics to validate and launch tests. Natera's products are available through its direct sales force and a network of laboratory and distribution partners.

Notably, the company has strategic partnerships with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays, and with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera is headquartered in Austin, Texas, and can be found online at https://www.natera.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for NTRA - Natera  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for NTRA - Natera  - Stock Price & Dividends

NTRA Stock Overview

Market Cap in USD 13,758m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2015-07-02

NTRA Stock Ratings

Growth 5y 53.4
Fundamental -44.3
Dividend 0.00
Rel. Performance vs Sector 3.65
Analysts 4.56/5
Fair Price Momentum 118.41 USD
Fair Price DCF -

NTRA Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

NTRA Growth Ratios

Growth 12m 114.93%
Growth Correlation 12m 78%
Growth Correlation 3m 61%
CAGR 5y 32.18%
CAGR/Mean DD 5y 0.99
Sharpe Ratio 12m 2.28
Alpha vs SP500 12m 83.92
Beta vs SP500 5y weekly 1.45
ValueRay RSI 15.46
Volatility GJR Garch 1y 35.25%
Price / SMA 50 -2.39%
Price / SMA 200 35.59%
Current Volume 1717.5k
Average Volume 20d 1303.7k

External Links for NTRA Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of NTRA stocks?
As of July 21, 2024, the stock is trading at USD 105.98 with a total of 1,717,489 shares traded.
Over the past week, the price has changed by -5.04%, over one month by -1.14%, over three months by +24.27% and over the past year by +126.50%.
What are the forecast for NTRA stock price target?
According to ValueRays Forecast Model, NTRA Natera will be worth about 132.9 in July 2025. The stock is currently trading at 105.98. This means that the stock has a potential upside of +25.39%.
Issuer Forecast Upside
Wallstreet Target Price 123.4 16.4
Analysts Target Price 71.2 -32.8
ValueRay Target Price 132.9 25.4